Table 2 The components involved for each type of signaling with available inhibitors and their current state in clinical trials.

From: Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer

Signal path element

Inhibitor

Mode of action

Clinical trial status

Reference

Smo inhibitors

Vismodegib

Keeped the transcription factors GLI1/2 in an inactive state.

Phase I and II trials

[142,143,144]

sonidegib

Blocked the abnormal activation of the HH signaling pathway.

Phase I and II trials

[145]

Cyclopamine

Binded to the seven-helix receptor of Smo protein.

Preclinical

[149]

Inoscavin A

Reduced the expression levels of key proteins in the Hh signaling pathway, such as Shh, Ptch1, Smo and Gli1.

Preclinical

[151]

Gli inhibitors

Garcinone C

Inhibited AKT phosphorylation and induced G0/G1 arrest.

Preclinical

[152]

GANT61

Its hydrolysate, GANT61-D, binded to a specific region of Gli1 protein.

Preclinical

[155]

HH78

competitively binded to SMO and suppressed GLI transcriptional activity.

Preclinical

[156]

ATO

Directly inhibited the transcriptional activity of GLI1 protein and blocked HH/GLI signaling pathway

Phase I, II and III trials

[146]

PI4KB inhibitors

Pipinib

Selective inhibition of PI4KB reduced PI4P levels and prevented HH-mediated ciliary localization of Smo protein.

Preclinical

[154]

  1. Smo inhibitors (e.g., Vismodegib, Sonidegib, Cyclopamine, Inoscavin A), Gli inhibitors (e.g., Garcinone C, GANT61, HH78, ATO), and PI4KB inhibitors (e.g., Pipinib) are among the inhibitors listed in Table 2 that target distinct elements of the Hh signaling pathway. These inhibitors function in various ways. The clinical trial status of these inhibitors, including those undergoing phase I/II clinical trials and those still undergoing pre-clinical research, is also listed in Table 2. These findings offer a scientific foundation for upcoming medication development and clinical care, as well as a valuable resource for comprehending the mechanism of action and potential clinical uses of Hh signaling pathway inhibitors.Hedgehog signaling pathway inhibitor in the clinical trials from Public Chemical Database (https://pubchem.ncbi.nlm.nih.gov/).